β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study

The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated wit...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Leila Karimi [verfasserIn] Lies Lahousse [verfasserIn] Mohsen Ghanbari [verfasserIn] Natalie Terzikhan [verfasserIn] André G. Uitterlinden [verfasserIn] Johan van der Lei [verfasserIn] Guy G. Brusselle [verfasserIn] Bruno H. Stricker [verfasserIn] Katia M. C. Verhamme [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2019

Schlagwörter:	chronic obstructive pulmonary disease inhaled β2-agonists exacerbations

Übergeordnetes Werk:	In: Journal of Clinical Medicine - MDPI AG, 2013, 8(2019), 11, p 1835
Übergeordnetes Werk:	volume:8 ; year:2019 ; number:11, p 1835

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/jcm8111835

Katalog-ID:	DOAJ016972627

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ016972627
003	DE-627
005	20230310084838.0
007	cr uuu---uuuuu
008	230226s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/jcm8111835 \|2 doi
035			\|a (DE-627)DOAJ016972627
035			\|a (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Leila Karimi \|e verfasserin \|4 aut
245	1	0	\|a β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists.
650		4	\|a chronic obstructive pulmonary disease
650		4	\|a inhaled β2-agonists
650		4	\|a exacerbations
650		4	\|a <i<adrb2 gene</i<
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Lies Lahousse \|e verfasserin \|4 aut
700	0		\|a Mohsen Ghanbari \|e verfasserin \|4 aut
700	0		\|a Natalie Terzikhan \|e verfasserin \|4 aut
700	0		\|a André G. Uitterlinden \|e verfasserin \|4 aut
700	0		\|a Johan van der Lei \|e verfasserin \|4 aut
700	0		\|a Guy G. Brusselle \|e verfasserin \|4 aut
700	0		\|a Bruno H. Stricker \|e verfasserin \|4 aut
700	0		\|a Katia M. C. Verhamme \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Clinical Medicine \|d MDPI AG, 2013 \|g 8(2019), 11, p 1835 \|w (DE-627)718632478 \|w (DE-600)2662592-1 \|x 20770383 \|7 nnns
773	1	8	\|g volume:8 \|g year:2019 \|g number:11, p 1835
856	4	0	\|u https://doi.org/10.3390/jcm8111835 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2077-0383/8/11/1835 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2077-0383 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 8 \|j 2019 \|e 11, p 1835

Indexfelder

author_variant	l k lk l l ll m g mg n t nt a g u agu j v d l jvdl g g b ggb b h s bhs k m c v kmcv
matchkey_str	article:20770383:2019----::u2uarnrircpoear2meeoyopimadikfodxc
hierarchy_sort_str	2019
publishDate	2019
allfields	10.3390/jcm8111835 doi (DE-627)DOAJ016972627 (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e DE-627 ger DE-627 rakwb eng Leila Karimi verfasserin aut β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists. chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i< Medicine R Lies Lahousse verfasserin aut Mohsen Ghanbari verfasserin aut Natalie Terzikhan verfasserin aut André G. Uitterlinden verfasserin aut Johan van der Lei verfasserin aut Guy G. Brusselle verfasserin aut Bruno H. Stricker verfasserin aut Katia M. C. Verhamme verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 8(2019), 11, p 1835 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:8 year:2019 number:11, p 1835 https://doi.org/10.3390/jcm8111835 kostenfrei https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e kostenfrei https://www.mdpi.com/2077-0383/8/11/1835 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 11, p 1835
spelling	10.3390/jcm8111835 doi (DE-627)DOAJ016972627 (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e DE-627 ger DE-627 rakwb eng Leila Karimi verfasserin aut β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists. chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i< Medicine R Lies Lahousse verfasserin aut Mohsen Ghanbari verfasserin aut Natalie Terzikhan verfasserin aut André G. Uitterlinden verfasserin aut Johan van der Lei verfasserin aut Guy G. Brusselle verfasserin aut Bruno H. Stricker verfasserin aut Katia M. C. Verhamme verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 8(2019), 11, p 1835 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:8 year:2019 number:11, p 1835 https://doi.org/10.3390/jcm8111835 kostenfrei https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e kostenfrei https://www.mdpi.com/2077-0383/8/11/1835 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 11, p 1835
allfields_unstemmed	10.3390/jcm8111835 doi (DE-627)DOAJ016972627 (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e DE-627 ger DE-627 rakwb eng Leila Karimi verfasserin aut β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists. chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i< Medicine R Lies Lahousse verfasserin aut Mohsen Ghanbari verfasserin aut Natalie Terzikhan verfasserin aut André G. Uitterlinden verfasserin aut Johan van der Lei verfasserin aut Guy G. Brusselle verfasserin aut Bruno H. Stricker verfasserin aut Katia M. C. Verhamme verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 8(2019), 11, p 1835 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:8 year:2019 number:11, p 1835 https://doi.org/10.3390/jcm8111835 kostenfrei https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e kostenfrei https://www.mdpi.com/2077-0383/8/11/1835 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 11, p 1835
allfieldsGer	10.3390/jcm8111835 doi (DE-627)DOAJ016972627 (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e DE-627 ger DE-627 rakwb eng Leila Karimi verfasserin aut β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists. chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i< Medicine R Lies Lahousse verfasserin aut Mohsen Ghanbari verfasserin aut Natalie Terzikhan verfasserin aut André G. Uitterlinden verfasserin aut Johan van der Lei verfasserin aut Guy G. Brusselle verfasserin aut Bruno H. Stricker verfasserin aut Katia M. C. Verhamme verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 8(2019), 11, p 1835 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:8 year:2019 number:11, p 1835 https://doi.org/10.3390/jcm8111835 kostenfrei https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e kostenfrei https://www.mdpi.com/2077-0383/8/11/1835 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 11, p 1835
allfieldsSound	10.3390/jcm8111835 doi (DE-627)DOAJ016972627 (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e DE-627 ger DE-627 rakwb eng Leila Karimi verfasserin aut β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists. chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i< Medicine R Lies Lahousse verfasserin aut Mohsen Ghanbari verfasserin aut Natalie Terzikhan verfasserin aut André G. Uitterlinden verfasserin aut Johan van der Lei verfasserin aut Guy G. Brusselle verfasserin aut Bruno H. Stricker verfasserin aut Katia M. C. Verhamme verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 8(2019), 11, p 1835 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:8 year:2019 number:11, p 1835 https://doi.org/10.3390/jcm8111835 kostenfrei https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e kostenfrei https://www.mdpi.com/2077-0383/8/11/1835 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2019 11, p 1835
language	English
source	In Journal of Clinical Medicine 8(2019), 11, p 1835 volume:8 year:2019 number:11, p 1835
sourceStr	In Journal of Clinical Medicine 8(2019), 11, p 1835 volume:8 year:2019 number:11, p 1835
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i< Medicine R
isfreeaccess_bool	true
container_title	Journal of Clinical Medicine
authorswithroles_txt_mv	Leila Karimi @@aut@@ Lies Lahousse @@aut@@ Mohsen Ghanbari @@aut@@ Natalie Terzikhan @@aut@@ André G. Uitterlinden @@aut@@ Johan van der Lei @@aut@@ Guy G. Brusselle @@aut@@ Bruno H. Stricker @@aut@@ Katia M. C. Verhamme @@aut@@
publishDateDaySort_date	2019-01-01T00:00:00Z
hierarchy_top_id	718632478
id	DOAJ016972627
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ016972627</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310084838.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/jcm8111835</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ016972627</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd11d00eaace64dd18aa405a6d530059e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Leila Karimi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg &gt; Gly) and rs1042714 (27Gln &gt; Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic obstructive pulmonary disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inhaled β2-agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">exacerbations</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<adrb2 gene</i<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lies Lahousse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohsen Ghanbari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Terzikhan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">André G. Uitterlinden</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Johan van der Lei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guy G. Brusselle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruno H. Stricker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katia M. C. Verhamme</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical Medicine</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">8(2019), 11, p 1835</subfield><subfield code="w">(DE-627)718632478</subfield><subfield code="w">(DE-600)2662592-1</subfield><subfield code="x">20770383</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:11, p 1835</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/jcm8111835</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2077-0383/8/11/1835</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2077-0383</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2019</subfield><subfield code="e">11, p 1835</subfield></datafield></record></collection>
author	Leila Karimi
spellingShingle	Leila Karimi misc chronic obstructive pulmonary disease misc inhaled β2-agonists misc exacerbations misc <i<adrb2 gene</i< misc Medicine misc R β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study
authorStr	Leila Karimi
ppnlink_with_tag_str_mv	@@773@@(DE-627)718632478
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	20770383
topic_title	β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study chronic obstructive pulmonary disease inhaled β2-agonists exacerbations <i<adrb2 gene</i<
topic	misc chronic obstructive pulmonary disease misc inhaled β2-agonists misc exacerbations misc <i<adrb2 gene</i< misc Medicine misc R
topic_unstemmed	misc chronic obstructive pulmonary disease misc inhaled β2-agonists misc exacerbations misc <i<adrb2 gene</i< misc Medicine misc R
topic_browse	misc chronic obstructive pulmonary disease misc inhaled β2-agonists misc exacerbations misc <i<adrb2 gene</i< misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Clinical Medicine
hierarchy_parent_id	718632478
hierarchy_top_title	Journal of Clinical Medicine
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)718632478 (DE-600)2662592-1
title	β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study
ctrlnum	(DE-627)DOAJ016972627 (DE-599)DOAJd11d00eaace64dd18aa405a6d530059e
title_full	β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study
author_sort	Leila Karimi
journal	Journal of Clinical Medicine
journalStr	Journal of Clinical Medicine
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2019
contenttype_str_mv	txt
author_browse	Leila Karimi Lies Lahousse Mohsen Ghanbari Natalie Terzikhan André G. Uitterlinden Johan van der Lei Guy G. Brusselle Bruno H. Stricker Katia M. C. Verhamme
container_volume	8
format_se	Elektronische Aufsätze
author-letter	Leila Karimi
doi_str_mv	10.3390/jcm8111835
author2-role	verfasserin
title_sort	β<sub<2</sub<-adrenergic receptor <em<(adrb2) </em<gene polymorphisms and risk of copd exacerbations: the rotterdam study
title_auth	β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study
abstract	The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists.
abstractGer	The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists.
abstract_unstemmed	The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg > Gly) and rs1042714 (27Gln > Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	11, p 1835
title_short	β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study
url	https://doi.org/10.3390/jcm8111835 https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e https://www.mdpi.com/2077-0383/8/11/1835 https://doaj.org/toc/2077-0383
remote_bool	true
author2	Lies Lahousse Mohsen Ghanbari Natalie Terzikhan André G. Uitterlinden Johan van der Lei Guy G. Brusselle Bruno H. Stricker Katia M. C. Verhamme
author2Str	Lies Lahousse Mohsen Ghanbari Natalie Terzikhan André G. Uitterlinden Johan van der Lei Guy G. Brusselle Bruno H. Stricker Katia M. C. Verhamme
ppnlink	718632478
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/jcm8111835
up_date	2024-07-03T23:48:34.322Z
_version_	1803603688110948352
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ016972627</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310084838.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/jcm8111835</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ016972627</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd11d00eaace64dd18aa405a6d530059e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Leila Karimi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The role of the β<sub<2</sub<-adrenergic receptor (<i<ADRB2</i<) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between <i<ADRB2 </i<variants and the risk of exacerbations in COPD patients treated with inhaled β<sub<2</sub<-agonists. Within the Rotterdam Study, a population-based cohort study, we followed 1,053 COPD patients until the first COPD exacerbation or end of follow-up and extracted rs1042713 (16Arg &gt; Gly) and rs1042714 (27Gln &gt; Glu) in <i<ADRB2</i<. Exposure to inhaled β<sub<2</sub<-agonists was categorised into current, past or non-use on the index date (date of COPD exacerbation for cases and on the same day of follow-up for controls). COPD exacerbations were defined as acute episodes of worsening symptoms requiring systemic corticosteroids and/or antibiotics (moderate exacerbations), or hospitalization (severe exacerbations). The associations between <i<ADRB2 </i<variants and COPD exacerbations were assessed using Cox proportional hazards models, adjusting for age, sex, use of inhaled corticosteroids, daily dose of β<sub<2</sub<-agonists, and smoking. In current users of β<sub<2</sub<-agonists, the risk of COPD exacerbation decreased by 30% (hazard ratio (HR); 0.70, 95% CI: 0.59–0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR; 0.80, 95% CI: 0.69–0.94) for each copy of the Gln allele of rs1042714. Furthermore, current users carrying the Arg16/Gln27 haplotype had a significantly lower risk (HR; 0.70, 95% CI: 0.59–0.85) of COPD exacerbation compared to the Gly16/Glu27 haplotype. In conclusion, we observed that the Arg16/Gln27 haplotype in<i< ADRB2</i< was associated with a reduced risk of COPD exacerbation in current users of inhaled β<sub<2</sub<-agonists.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic obstructive pulmonary disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inhaled β2-agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">exacerbations</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<adrb2 gene</i<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lies Lahousse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohsen Ghanbari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natalie Terzikhan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">André G. Uitterlinden</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Johan van der Lei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guy G. Brusselle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruno H. Stricker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katia M. C. Verhamme</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical Medicine</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">8(2019), 11, p 1835</subfield><subfield code="w">(DE-627)718632478</subfield><subfield code="w">(DE-600)2662592-1</subfield><subfield code="x">20770383</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:11, p 1835</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/jcm8111835</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d11d00eaace64dd18aa405a6d530059e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2077-0383/8/11/1835</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2077-0383</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2019</subfield><subfield code="e">11, p 1835</subfield></datafield></record></collection>
score	7.3996086

Nicht das Richtige dabei?

Schreiben Sie uns!

β<sub<2</sub<-Adrenergic Receptor <em<(ADRB2) </em<Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?